Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosaic HIV-1 Envelope Trimer Vaccine Trial in PLWH
NCT06449196Phase 1Withdrawn
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Aug 2024
- Primary completion
- Feb 2025
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, open-label trial of mosaic HIV-1 envelope trimer immunogens in human immunodeficiency virus infection (HIV) (2 arms), sponsored by International AIDS Vaccine Initiative. Primary endpoint: Incidence of reactogenicity events, adverse events and serious adverse events at 15 months. Planned start Aug 2024; status: withdrawn.
02
Drugs
mosaic HIV-1 envelope trimer immunogens
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06449196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06449196.